Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.
The Group
First quarter 2026
Income amounted to TSEK 443 (140).
Loss before tax totalled TSEK 11,780 (loss: 10,661).
Loss per share was SEK 0.02 (loss: 0.02).
The Parent company
First quarter 2026
Income amounted to TSEK 443 (140).
Loss before tax totalled TSEK 10,704 (loss: 8,574).
Significant events in the first quarter of 2026
» Xintela announces that the company’s Phase I/IIa clinical study of XSTEM® in patients with hard-to-heal venous leg ulcers has been completed with the final follow-up visit of the last patient. XSTEM, consisting of allogeneic (donor-derived) integrin α10ß1-selected mesenchymal stem cells, is being developed and manufactured by Xintela.
Significant events after the end of the period
» The results from Xintela’s preclinical study of EQSTEM® in horses with post-traumatic osteoarthritis have previously been published in the scientific journal Cartilage. The results demonstrate reduced pain and less cartilage damage following treatment with the stem cell product EQSTEM, indicating a disease-modifying effect of EQSTEM. The publication has now been awarded Best Basic Science Article 2025.
» Xintela announces that the United States Patent and Trademark Office has granted a patent covering the use of the
company’s stem cell product XSTEM® for the treatment and regeneration of skin defects, including hard-to-heal (chronic) wounds. The patent protects XSTEM in the United States until June 7, 2043.
» Xintela announces that the Japan Patent Office has granted a patent protecting the company’s stem cell product XSTEM® for the treatment of acute respiratory distress syndrome (ARDS) and related diseases. The patent may remain in force in Japan until May 7, 2041.
The complete report is available for download below and on the company’s website https://xintela.se/en/investors/#financial-reports
